News

Company News

For more information about the history of the company and our technology, click here.

 
Talaris Therapeutics lands $115M in venture capital funding
Louisville Business First: The is the second time in about 18 months that this company has turned heads with its...  READ MORE
Talaris awarded 2020 Citeline Award for Clinical Trial Result of the Year
On September 17, 2020, Talaris was awarded the 2020 Citeline Award for Clinical Trial Result of the Year.  This award...  READ MORE
Talaris CEO: New partnership could expand access to ‘Holy Grail’ treatment for organ transplant patients
Louisville Business First: The Louisville-based biotech could see it gamechanging treatment expand to many more people in need an organ...  READ MORE
Cell Therapy Allows Organ Recipient to Be Off Anti-Rejection Medication
SpectrumNews1: LOUISVILLE, Ky. — Robert Waddell is a kidney recipient, but he hasn’t taken immunosuppressants for 10 years. It’s because...  READ MORE
Cell Therapy FCR001 to Enter Phase 1/2a Trial for Diffuse Cutaneous SSc
Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse...  READ MORE
Talaris to tackle new disease with ‘Holy Grail’ of immunotherapy
The high-potential Louisville-based biotech is expanding its study of what kinds of diseases its signature treatment could resolve with a...  READ MORE
Health Care Heroes 2020
Members of the Louisville business community gathered Tuesday night to recognize and celebrate 31 health care professionals at Louisville Business...  READ MORE
“Freedom” from Immunosuppression in Solid Organ Transplantation
KidneyNews features the Talaris approach and FREEDOM-1 Study “This study is the most exciting development to date in the field...  READ MORE
20 People to Know in Health Care: Scott Requadt
Louisville Business First features Scott Requadt in their 20 People to Know in Healthcare: FULL STORY  READ MORE
Talaris is honored to be named a life science startup to watch by BioSpace
Talaris is honored to be named a life science startup to watch by BioSpace. 2020 is a big year for...  READ MORE
FDA approves next phase of medical breakthrough in kidney transplants
@WDRBNews reports on Talaris’ Phase 3 trial initiation which will bring our cell therapy to hospitals across the country. Hear...  READ MORE
UofL innovators honored at inaugural EPIC Innovation Awards
This week Talaris founder Dr. Suzanne Ildstad was honored with the Innovator of the Year Award at the @uofl inaugural...  READ MORE
The Winners of the 2019 Xconomy Awards Boston
…after much discussion and debate among our judges and the editors, we decided that these winners represent the best of...  READ MORE
Talaris Therapeutics selected as a finalist in 2019 Xconomy Awards
XCONOMY: The editors and judges of Xconomy have narrowed down an impressive list of nearly 300 nominees for the 2019...  READ MORE
$100M for Talaris Gives Surgeon a Shot to Reinvent Organ Transplants
XCONOMY: When Novartis dissolved its gene and cell therapy unit a few years ago, a bunch of projects the Swiss...  READ MORE
Regenerex gets new CEO, new funding and new name: Talaris Therapeutics
FIERCE BIOTECH: As it gears up to move its lead cell therapy into phase 3, Regenerex has closed a $100...  READ MORE
Local researchers celebrate medical breakthrough in post-transplant care
WDRB.Com | LOUISVILLE, Ky. (WDRB) — A group of local researchers plan to use a $100 million Series A financing...  READ MORE
On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round
ENDPOINTS NEWS: As a transplant surgeon by training, Suzanne Ildstad understood the plight of her patients all too well: The...  READ MORE